CIDP associated with LM1 antibodies
Evidence-based neurology checklist on cidp associated with lm1 antibodies: Demographic features This may mark a subclass of CIDP It is present in 10% of cases It is more frequent in elderly subjects Clinical features Treatment
Demographic features
- This may mark a subclass of CIDP
- It is present in 10% of cases
- It is more frequent in elderly subjects
Clinical features
Treatment
References
- Ogata H, Yamasaki R, Hiwatashi A, et al. Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Ann Clin Transl Neurol 2015; 2:960-971.
- Kuwahara M, Suzuki H, Samukawa M, Hamada Y, Takada K, Kusonoki S. Clinical features of CIDP with LM1-associated antibodies. JNNP 2013; 84:573-575.
